Other Earnings and Cash Flow Stats:
ASTRAZENECA PLC ( AZN ) Net Income TTM ($MM) is 7462.00
ASTRAZENECA PLC ( AZN ) Operating Income TTM ($MM) is 11031.00
ASTRAZENECA PLC ( AZN ) Owners' Earnings Annual ($MM) is 9178.32
ASTRAZENECA PLC ( AZN ) Current Price to Owners' Earnings ratio is 22.88
ASTRAZENECA PLC ( AZN ) EBITDA TTM ($MM) is 16256.00
ASTRAZENECA PLC ( AZN ) EBITDA Margin is 30.30%
Capital Allocation:
ASTRAZENECA PLC ( AZN ) has paid 0.50 dividends per share and bought back -4.0 million shares in the past 12 months
ASTRAZENECA PLC ( AZN ) has increased its debt by 4112.0 million USD in the last 12 months
Capital Structure:
ASTRAZENECA PLC ( AZN ) Interest-bearing Debt ($MM) as of last quarter is 33825
ASTRAZENECA PLC ( AZN ) Annual Working Capital Investments ($MM) are -298
ASTRAZENECA PLC ( AZN ) Book Value ($MM) as of last quarter is 40805
ASTRAZENECA PLC ( AZN ) Debt/Capital as of last quarter is 85%
Other Balance Sheet Stats:
ASTRAZENECA PLC ( AZN ) has 4797 million in cash on hand as of last quarter
ASTRAZENECA PLC ( AZN ) has 25926 million of liabilities due within 12 months, and long term debt 32292 as of last quarter
ASTRAZENECA PLC ( AZN ) has 3124 common shares outstanding as of last quarter
ASTRAZENECA PLC ( AZN ) has 0 million USD of preferred stock value
Academic Scores:
ASTRAZENECA PLC ( AZN ) Altman Z-Score is 2.78 as of last quarter
ASTRAZENECA PLC ( AZN ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
ASTRAZENECA PLC ( AZN ) largest shareholder is owning shares at 0.00 ($MM) value
Plc Astrazeneca(an insider) Bought 425000 shares of ASTRAZENECA PLC ( AZN ) for the amount of $8075000.00 on 2019-10-07
0.01% of ASTRAZENECA PLC ( AZN ) is held by insiders, and 16.76% is held by institutions
ASTRAZENECA PLC ( AZN ) went public on 1993-05-12
Other ASTRAZENECA PLC ( AZN ) financial metrics:
FCF:7946.00
Unlevered Free Cash Flow:7239.00
EPS:1.83
Operating Margin:15.53
Gross Profit Margin:77.29
Div. Payout Ratio%:20.93
Div. Growth YoY%:-65.52
Equity Return%:14.04
Beta:0.50
Buffet's Owners Earnings:9178.32
Price to Owner's Earnings:22.88
About ASTRAZENECA PLC ( AZN ) :
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of preion medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
DISCLAIMER
This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.